Ascentage Pharma Group International (AAPG) Common Equity: 2022-2024

  • Ascentage Pharma Group International's Common Equity rose 282.88% to $37.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $37.6 million, marking a year-over-year increase of 282.88%. This contributed to the annual value of $37.6 million for FY2024, which is 275.80% up from last year.
  • Latest data reveals that Ascentage Pharma Group International reported Common Equity of $37.6 million as of Q4 2024, which was up 282.88% from $9.8 million recorded in Q4 2023.
  • Ascentage Pharma Group International's Common Equity's 5-year high stood at $57.5 million during Q4 2022, with a 5-year trough of $9.8 million in Q4 2023.
  • For the 3-year period, Ascentage Pharma Group International's Common Equity averaged around $34.9 million, with its median value being $37.6 million (2024).
  • Per our database at Business Quant, Ascentage Pharma Group International's Common Equity crashed by 82.93% in 2023 and then soared by 282.88% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Common Equity (Quarterly) stood at $57.5 million in 2022, then slumped by 82.93% to $9.8 million in 2023, then surged by 282.88% to $37.6 million in 2024.
  • Its last three reported values are $37.6 million in Q4 2024, $9.8 million for Q4 2023, and $57.5 million during Q4 2022.